Nothing Special   »   [go: up one dir, main page]

MA38404A1 - Nouveaux dérivés de pyridine - Google Patents

Nouveaux dérivés de pyridine

Info

Publication number
MA38404A1
MA38404A1 MA38404A MA38404A MA38404A1 MA 38404 A1 MA38404 A1 MA 38404A1 MA 38404 A MA38404 A MA 38404A MA 38404 A MA38404 A MA 38404A MA 38404 A1 MA38404 A1 MA 38404A1
Authority
MA
Morocco
Prior art keywords
pyridine derivatives
new pyridine
new
formula
compound
Prior art date
Application number
MA38404A
Other languages
English (en)
Other versions
MA38404B1 (fr
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Didier Rombach
Olivier Gavelle
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38404A1 publication Critical patent/MA38404A1/fr
Publication of MA38404B1 publication Critical patent/MA38404B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (i) dans laquelle a et r1 à r4 sont tels que définis dans la description et dans les revendications. Le composé de formule (i) peut être utilisé comme médicament.
MA38404A 2013-03-26 2014-03-24 Nouveaux dérivés de pyridine MA38404B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26
PCT/EP2014/055797 WO2014154612A1 (fr) 2013-03-26 2014-03-24 Nouveaux dérivés de pyridine

Publications (2)

Publication Number Publication Date
MA38404A1 true MA38404A1 (fr) 2017-01-31
MA38404B1 MA38404B1 (fr) 2017-09-29

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38404A MA38404B1 (fr) 2013-03-26 2014-03-24 Nouveaux dérivés de pyridine

Country Status (34)

Country Link
US (2) US10308659B2 (fr)
EP (1) EP2978755B1 (fr)
JP (1) JP6500010B2 (fr)
KR (1) KR20150135458A (fr)
CN (1) CN105121436B (fr)
AR (1) AR095721A1 (fr)
AU (1) AU2014243190B2 (fr)
BR (1) BR112015024272A2 (fr)
CA (1) CA2899168A1 (fr)
CL (1) CL2015002835A1 (fr)
CR (1) CR20150440A (fr)
DK (1) DK2978755T3 (fr)
EA (1) EA027569B1 (fr)
ES (1) ES2661737T3 (fr)
HK (1) HK1211938A1 (fr)
HR (1) HRP20180371T1 (fr)
HU (1) HUE036934T2 (fr)
IL (1) IL240496B (fr)
LT (1) LT2978755T (fr)
MA (1) MA38404B1 (fr)
MX (1) MX365921B (fr)
MY (1) MY174000A (fr)
NO (1) NO2978755T3 (fr)
PE (1) PE20151559A1 (fr)
PH (1) PH12015501933B1 (fr)
PL (1) PL2978755T3 (fr)
PT (1) PT2978755T (fr)
RS (1) RS56927B1 (fr)
SG (1) SG11201507994QA (fr)
SI (1) SI2978755T1 (fr)
TW (1) TWI628174B (fr)
UA (1) UA116239C2 (fr)
WO (1) WO2014154612A1 (fr)
ZA (1) ZA201505251B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708341B2 (en) * 2014-06-09 2017-07-18 Sumitomo Chemical Company, Limited Method for producing pyridine compound
DK3386951T3 (en) * 2015-12-09 2020-04-27 Hoffmann La Roche Phenylderivater som cannabinoidreceptor-2-agonister
TWI737763B (zh) * 2016-07-07 2021-09-01 美商陶氏農業科學公司 製備4-烷氧基-3-(醯基或烷基)氧基吡啶醯胺之方法
TWI829634B (zh) * 2017-04-06 2024-01-21 美商富曼西公司 殺真菌之噁二唑
EP3642200B1 (fr) * 2017-06-20 2023-05-03 F. Hoffmann-La Roche AG Dérivés de pyridines
WO2019003956A1 (fr) * 2017-06-27 2019-01-03 住友化学株式会社 Composé oxadiazole et utilisation associée
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
WO2020002314A1 (fr) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Ligand du récepteur cannabinoïde 2 radiomarqué
WO2020002270A1 (fr) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Dérivés de pyridine et de pyrazine en tant qu'agonistes de cannabinoïde 2 préférentiels
KR20210028202A (ko) 2018-06-27 2021-03-11 에프. 호프만-라 로슈 아게 칸나비노이드 수용체 2의 억제제로서 신규한 피리딘 및 피라진 화합물
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
WO2023069721A2 (fr) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Dérivés de l'oxazole, de l'oxadiazole et de l'indole pour l'inhibition d'usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
KR20090054984A (ko) * 2006-08-07 2009-06-01 아이언우드 파마슈티컬스, 인코포레이티드 인돌 화합물
EP2211619A1 (fr) * 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. 1,2,4-oxadiazoles substitués et leurs analogues comme modulateurs des récepteurs cb2, utiles dans le traitement de la douleur et de maladies respiratoires et non respiratoires
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
EA027780B1 (ru) 2012-12-07 2017-08-31 Ф.Хоффманн-Ля Рош Аг Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
US9512141B2 (en) 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
EP2928868B1 (fr) 2012-12-07 2017-08-09 F. Hoffmann-La Roche AG Pyridine-2-amides utiles comme agonistes de cb2
EP3357918A1 (fr) 2012-12-07 2018-08-08 F. Hoffmann-La Roche AG Nouveaux dérivés de pyridine
MY176797A (en) 2013-03-07 2020-08-21 Hoffmann La Roche Novel pyrazol derivatives
WO2015150438A1 (fr) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-carboxamides bisubstitués en 5,6 servant d'agonistes du récepteur cannabinoïde
MX2016012689A (es) 2014-04-04 2016-12-14 Hoffmann La Roche Piridin-2-amidas utiles como agonistas del receptor 2 cannabinoide (cb2).

Also Published As

Publication number Publication date
BR112015024272A2 (pt) 2017-07-18
LT2978755T (lt) 2018-03-12
TWI628174B (zh) 2018-07-01
JP2016516737A (ja) 2016-06-09
MA38404B1 (fr) 2017-09-29
EP2978755B1 (fr) 2018-01-03
TW201518287A (zh) 2015-05-16
HRP20180371T1 (hr) 2018-04-06
MY174000A (en) 2020-03-03
CL2015002835A1 (es) 2016-05-20
RS56927B1 (sr) 2018-05-31
IL240496A0 (en) 2015-09-24
IL240496B (en) 2019-03-31
PL2978755T3 (pl) 2018-05-30
US20190248803A1 (en) 2019-08-15
CA2899168A1 (fr) 2014-10-02
PH12015501933A1 (en) 2016-01-11
PT2978755T (pt) 2018-02-26
JP6500010B2 (ja) 2019-04-10
US10308659B2 (en) 2019-06-04
EA027569B1 (ru) 2017-08-31
CN105121436A (zh) 2015-12-02
UA116239C2 (uk) 2018-02-26
PH12015501933B1 (en) 2016-01-11
HUE036934T2 (hu) 2018-08-28
KR20150135458A (ko) 2015-12-02
WO2014154612A1 (fr) 2014-10-02
SG11201507994QA (en) 2015-10-29
CN105121436B (zh) 2018-07-27
DK2978755T3 (en) 2018-03-05
MX2015013629A (es) 2016-02-18
EA201591567A1 (ru) 2016-01-29
AU2014243190A1 (en) 2015-07-30
AR095721A1 (es) 2015-11-04
ZA201505251B (en) 2016-07-27
PE20151559A1 (es) 2015-11-05
MX365921B (es) 2019-06-20
US20160016968A1 (en) 2016-01-21
AU2014243190B2 (en) 2018-07-19
EP2978755A1 (fr) 2016-02-03
SI2978755T1 (en) 2018-03-30
ES2661737T3 (es) 2018-04-03
CR20150440A (es) 2015-10-08
NO2978755T3 (fr) 2018-06-02
HK1211938A1 (en) 2016-06-03

Similar Documents

Publication Publication Date Title
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA38238A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201591527A1 (ru) Новые производные пиридина
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38555B1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201500931A1 (ru) Производные пиридин-4-ила
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
AR095097A1 (es) Compuestos de fenoxietoxi
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения
BR112015011351A2 (pt) composição farmacêutica de difenidol de liberação sustentada
MA43667B1 (fr) Nouveaux dérivés de pyrrolidine
EA201501177A1 (ru) Фармацевтические композиции